Australia markets closed

Tempus AI, Inc (TEM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
38.05-2.65 (-6.51%)
At close: 04:00PM EDT
38.05 0.00 (0.00%)
Pre-market: 04:16AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close40.70
Open40.70
Bid36.13 x 1200
Ask39.59 x 1200
Day's range37.68 - 40.93
52-week range22.89 - 45.11
Volume622,180
Avg. volume1,634,066
Market cap6.272B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-7.79
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est46.00
  • Business Wire

    Tempus to Report Second Quarter 2024 Financial Results on August 6

    CHICAGO, July 17, 2024--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day.

  • Business Wire

    Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests

    CHICAGO, July 16, 2024--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space. Additionally, Tempus is collaborating with other partners, like Cleveland Clinic, to b

  • Business Wire

    Tempus Surpasses 500 Research Publications

    CHICAGO, July 10, 2024--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has reached a research milestone of over 500 research publications. In the last eight years, Tempus has invested in rigorous scientific research to validate its diagnostic offerings, while also working with biopharma and academic collaborators to publish research supported by the company’s multimodal data library. This research milestone includes published and/or acknowledged work,